A Phase II Trial of Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs ATA 230 (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Atara Biotherapeutics
- 01 Feb 2018 Planned end date changed from 1 Dec 2017 to 1 Jun 2018.
- 01 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
- 27 Feb 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.